RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Wayne W. Harding to Dopamine Antagonists

This is a "connection" page, showing publications Wayne W. Harding has written about Dopamine Antagonists.
Connection Strength

1.362
  1. Giri R, Namballa HK, Sarker A, Alberts I, Harding WW. Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines. Bioorg Med Chem Lett. 2020 08 15; 30(16):127305.
    View in: PubMed
    Score: 0.753
  2. Giri R, Namballa HK, Emogaje V, Harding WW. Structure-Activity Relationship Studies on 6-Chloro-1-phenylbenzazepines Leads to the Identification of a New Dopamine D1 Receptor Antagonist. Molecules. 2023 Aug 11; 28(16).
    View in: PubMed
    Score: 0.235
  3. Bennett A, Barrera E, Namballa H, Harding W, Ranaldi R. (-)-Stepholidine blocks expression, but not development, of cocaine conditioned place preference in rats. Neurosci Lett. 2020 08 24; 734:135151.
    View in: PubMed
    Score: 0.188
  4. Galaj E, Harding W, Ranaldi R. Dopamine D1 and D3 receptor interactions in cocaine reward and seeking in rats. Psychopharmacology (Berl). 2016 Dec; 233(23-24):3881-3890.
    View in: PubMed
    Score: 0.145
  5. Manuszak M, Harding W, Gadhiya S, Ranaldi R. (-)-Stepholidine reduces cue-induced reinstatement of cocaine seeking and cocaine self-administration in rats. Drug Alcohol Depend. 2018 08 01; 189:49-54.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support